Filter results

Clinical Studies


  • Precision Pharmacogenomics in Cancer Patients Scottsdale/Phoenix, Ariz.

    THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer patients in order to improve quality of life (QOL) in patients receiving clinical care at Mayo Clinic.

Contact Us for the Latest Status

Closed for Enrollment

  • Mayo Clinic Cancer Genomics Service Line Biorepository Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn., Eau Claire, Wis.

    The goal of the study is to create a database of clinical information and a repository of biological specimens for genetic, molecular and microbiological research to better understand hereditary cancer and help develop new therapies and preventive strategies.

  • Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis Scottsdale/Phoenix, Ariz., Rochester, Minn.

    This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.